# A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

> **NCT00919854** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 27 (actual)

## Conditions studied

- Human Immunodeficiency Virus 1

## Interventions

- **DRUG:** Darunavir
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT00919854
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-08
- **Final completion:** 2011-02
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00919854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00919854, "A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00919854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*